Reproducibility of pharmacogenetics findings for paclitaxel in a heterogeneous population of patients with lung cancer.

ABSTRACT: Pharmacogenetics studies have identified several allelic variants with the potential to reduce toxicity and improve treatment outcome. The present study was designed to determine if such findings are reproducible in a heterogenous population of patients with lung cancer undergoing therapy with paclitaxel. We designed a prospective multi-institutional study that recruited n = 103 patients receiving paclitaxel therapy with a 5-year follow up. All patients were genotyped using the Drug Metabolizing Enzymes and Transporters (DMET) platform, which ascertains 1931 genotypes in 235 genes. Progression-free survival (PFS) of paclitaxel therapy and clinically-significant paclitaxel toxicities were classified and compared according to genotype. Initial screening revealed eleven variants that are asso

SUBMITTER: Sissung TM 

PROVIDER: S-EPMC6394902 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature